MAP2K1 and neoplasm: Our in vivo data using the H1792 xenograft model showed single agent selumetinib had enhanced anti-tumor effects compared to mTORC1/2 inhibitor AZD2014, suggesting that mutKRASG12C is more sensitive to MEK1/2 inhibition than mTORC1/2, despite having RICTOR amplification (Figure 6A).